This article is more than 5 years old. Information may no longer be current.

Presbyopia indication approved for Crystalens labeling

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ALISO VIEJO, Calif. — After discussions with U.S. regulators, eyeonics has been allowed to add the treatment of presbyopia to the indications for use of the Crystalens, according to a company spokesman.

“The addition of the presbyopia claim to our indications is a major enhancement to our labeling for the Crystalens,” said Mike Judy, vice president of marketing for eyeonics, in a press release from the company.

The revised labeling for the device will state that the Crystalens is intended “for the visual correction of aphakia secondary to the removal of a cataractous lens in adult patients with and without presbyopia.”